365 related articles for article (PubMed ID: 28178682)
1. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.
Heiland DH; Haaker G; Delev D; Mercas B; Masalha W; Heynckes S; Gäbelein A; Pfeifer D; Carro MS; Weyerbrock A; Prinz M; Schnell O
Oncotarget; 2017 Jun; 8(26):42214-42225. PubMed ID: 28178682
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
Ricklefs FL; Alayo Q; Krenzlin H; Mahmoud AB; Speranza MC; Nakashima H; Hayes JL; Lee K; Balaj L; Passaro C; Rooj AK; Krasemann S; Carter BS; Chen CC; Steed T; Treiber J; Rodig S; Yang K; Nakano I; Lee H; Weissleder R; Breakefield XO; Godlewski J; Westphal M; Lamszus K; Freeman GJ; Bronisz A; Lawler SE; Chiocca EA
Sci Adv; 2018 Mar; 4(3):eaar2766. PubMed ID: 29532035
[TBL] [Abstract][Full Text] [Related]
3. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
[TBL] [Abstract][Full Text] [Related]
6. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
[TBL] [Abstract][Full Text] [Related]
7. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
Shu C; Li Q
Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
[TBL] [Abstract][Full Text] [Related]
9. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
[TBL] [Abstract][Full Text] [Related]
11. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
[TBL] [Abstract][Full Text] [Related]
12. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
[TBL] [Abstract][Full Text] [Related]
14. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
Front Immunol; 2020; 11():588552. PubMed ID: 33329573
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression and prognostic impact in glioblastoma.
Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
[TBL] [Abstract][Full Text] [Related]
16. Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme-a retrospective cohort study.
Masood AB; Batool S; Bhatti SN; Ali A; Valko M; Jomova K; Kuca K
Front Immunol; 2023; 14():1202098. PubMed ID: 37529045
[TBL] [Abstract][Full Text] [Related]
17. Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme.
Heynckes S; Gaebelein A; Haaker G; Grauvogel J; Franco P; Mader I; Carro MS; Prinz M; Delev D; Schnell O; Heiland DH
Oncotarget; 2017 Sep; 8(43):74170-74177. PubMed ID: 29088776
[TBL] [Abstract][Full Text] [Related]
18. Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme.
Heiland DH; Simon-Gabriel CP; Demerath T; Haaker G; Pfeifer D; Kellner E; Kiselev VG; Staszewski O; Urbach H; Weyerbrock A; Mader I
Sci Rep; 2017 Mar; 7():43523. PubMed ID: 28266556
[TBL] [Abstract][Full Text] [Related]
19. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
[TBL] [Abstract][Full Text] [Related]
20. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
